Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2021, with a specific transaction date of July 22, 2021. The report serves as a transaction notification regarding a Principal Director or Manager (PDMR) rather than a periodic financial performance report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific insider transaction:
- Instrument: American Depositary Shares (ADSs)
- Transaction Type: Acquisition within the GSK Executive Supplemental Savings Plan
- Price: $39.23 per ADS
- Volume: 1,180.312 ADSs
- Exchange: New York Stock Exchange (XNYS)
Material Changes
The filing does not disclose material changes to the company's financial position or operations compared to prior periods. It solely reports a single acquisition event by an executive.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of an executive compensation-related transaction.
Key Facts for Investor Verification
- Executive Action: Dr. H Barron, Chief Scientific Officer and President, R&D, acquired 1,180.312 ADSs.
- Transaction Context: The purchase was made through the GSK Executive Supplemental Savings Plan, not a direct open-market purchase.
- Valuation: The transaction occurred at a price of $39.23 per share on July 22, 2021.
- Reporting Limitation: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or quarterly press releases for performance data.